Table 2. Outcomes by Quartile of Baseline Risk for Grades 2 to 3 BPD or Death.
| Outcome | Treatment group, No./total No. (%) | Relative risk (95% CI) | Risk difference (95% CI) | |
|---|---|---|---|---|
| Hydrocortisone | Placebo | |||
| Grades 2-3 BPD or death | ||||
| Quartile 1 | 51/108 (47.2) | 36/86 (41.9) | 1.13 (0.82 to 1.55) | 0.05 (−0.09 to 0.19) |
| Quartile 2 | 44/89 (49.4) | 56/109 (51.4) | 0.96 (0.73 to 1.27) | −0.02 (−0.16 to 0.12) |
| Quartile 3 | 64/97 (66.0) | 66/99 (66.7) | 0.99 (0.81 to 1.21) | −0.01 (−0.14 to 0.13) |
| Quartile 4 | 75/100 (75.0) | 80/100 (80.0) | 0.94 (0.81 to 1.09) | −0.05 (−0.17 to 0.07) |
| Overall | 234/394 (59.4) | 238/394 (60.4) | 0.98 (0.88 to 1.10) | −0.01 (−0.08 to 0.06) |
| Grades 2-3 BPD among survivors | ||||
| Quartile 1 | 50/107 (46.7) | 35/85 (41.2) | 1.13 (0.82 to 1.57) | 0.06 (−0.09 to 0.20) |
| Quartile 2 | 43/88 (48.9) | 53/106 (50.0) | 0.98 (0.73 to 1.30) | −0.01 (−0.15 to 0.13) |
| Quartile 3 | 56/89 (62.9) | 54/87 (62.1) | 1.01 (0.81 to 1.27) | 0.01 (−0.13 to 0.15) |
| Quartile 4 | 66/91 (72.5) | 68/88 (77.3) | 0.94 (0.79 to 1.11) | −0.05 (−0.17 to 0.08) |
| Overall | 215/375 (57.3) | 210/366 (57.4) | 1.00 (0.88 to 1.13) | −0.00 (−0.07 to 0.07) |
| Death by PMA of 36 wk | ||||
| Quartile 1 | 1/108 (0.9) | 1/86 (1.2) | 0.80 (0.05 to 12.55) | −0.00 (−0.03 to 0.03) |
| Quartile 2 | 1/89 (1.1) | 3/109 (2.8) | 0.41 (0.04 to 3.86) | −0.02 (−0.05 to 0.02) |
| Quartile 3 | 8/97 (8.2) | 12/99 (12.1) | 0.68 (0.29 to 1.59) | −0.04 (−0.12 to 0.05) |
| Quartile 4 | 9/100 (9.0) | 12/100 (12.0) | 0.75 (0.33 to 1.70) | −0.03 (−0.11 to 0.05) |
| Overall | 19/394 (4.8) | 28/394 (7.1) | 0.68 (0.39 to 1.19) | −0.02 (−0.06 to 0.01) |
Abbreviations: BPD, bronchopulmonary dysplasia; PMA, postmenstrual age.